System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
a-z list

Recombinant human TRAIL-R2 (DR5/ TNFRSF10B)/Fc Chimera

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  EXB0007 Lyophilized 0.05 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


Produced in HEK 293 cells. The extracellular domain of human TRAIL-R2 (aa 1 - 182) is fused to the Fc portion of human IgG1.


DR5 is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L).
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

Regulatory Status

Database Links


  • Loading control
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.


  • Unpublished.
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse Monoclonal to CD262 / TRAIL-R2 DR5-01-1 (IgG1)
  • Example Data

    DR5 SDS
    Fig. 1. SDS-PAGE

    Fig.1. SDS-PAGE Electrophoresis of TRAIL-R2 (DR5) / Fc recombinant protein (separating gel, 6% stacking gel; reducing conditions).
    Lane 1 to 4: TRAIL-R2 (DR5)/ Fc recombinant protein (2000 ng, 1000 ng, 500 ng, 200 ng per lane). Staining with Coomassie Blue.

    Fig.2. Western Blotting

    Fig.2. Western Blotting of TRAIL-R2 (DR5) / Fc recombinant protein. Reducing conditions.
    Lane 1 to 4: immunostaining with TRAIL-R2 (DR5) specific antibody DR5-01 (Cat. No. 11-461-C100; dilution 2 μg/ml ). Detection with Goat anti mouse / HRP secondary antibody. Amount of TRAIL-R2 (DR5)/ Fc recombinant protein loaded on each lane: (1) 50 ng, (2) 100 ng, (3) 200 ng, (4) 500 ng.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy